News und Analysen
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week
Agilent Announces Cash Dividend of 24.8 Cents per Share
Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on July 23, 2025, to all shareholders of
Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split
Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Pascal Soriot and Judy Gawlik Brown Named to Agilent Board of Directors
Agilent Technologies Inc. (NYSE: A) today announced that Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder and CEO of Downtown Advisory, have been elected to its Board of Directors
Uni-Bio Science Group Receives NMPA Approval for 金因康® (Diquafosol Sodium Eye Drops), Advancing Dry Eye Syndrome Treatment in China
EQS-News: M1 Kliniken AG: Strong Earnings Growth in 2024 – Strategic Focus on Global Market Leadership
Humana Foundation CEO, Tiffany Benjamin, Named to the Inaugural TIME100 Philanthropy List
The Humana Foundation, the philanthropic arm of Humana Inc. for the past 44 years, is proud to announce that Tiffany Benjamin, the foundation’s CEO, has been named to the inaugural TIME100
Agilent Announces My Green Lab Ecolabel 2.0 for the New Infinity III LC Series
Agilent Technologies Inc. (NYSE: A) today announced that the Infinity III LC Series — the company’s latest liquid chromatography (LC) instruments — are the first Agilent instruments to receive the
EQS-News: BRAIN Biotech announces buy-out of minorities, new continental European production site, and expansion of its Baking Application Center
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the
ICON releases its ICON Cares 2024 Report
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how the company is
Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend
Stockholders of Chemed Corporation (NYSE: CHE) today elected a slate of nine directors at the Company’s 2025 annual stockholders’ meeting.
Stockholders ratified the continuation of
EQS-News: Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS
STAAR Surgical Announces $30 Million Share Repurchase Authorization
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of
Agilent to Participate in Jefferies Global Healthcare Conference
Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at the Jefferies Global Healthcare Conference at
Premier Announces the Nation’s 15 Top Health Systems®
Premier, Inc. (NASDAQ: PINC) today announced the nation’s 15 Top Health Systems®.
Premier’s 15 Top Health Systems® annual study is the only study that includes a comprehensive analysis of the
LivaNova to Present at the Jefferies Global Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global
Simulations Plus Releases DILIsym® 11
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical
EQS-Adhoc: MAQUET Medical Systems AG submits squeeze-out request to Pulsion Medical Systems SE
EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
Chemed Corporation to Present at the 2025 RBC Global Healthcare Conference
Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, at approximately 9:30 a.m. (ET) at The
EQS-News: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2025 and